The antianginal ranolazine fails to improve glycemia in obese liver-specific pyruvate dehydrogenase deficient male mice.
Christina T SaedSeyed Amirhossein Tabatabaei DakhiliAmanda A GreenwellJordan S F ChanKunyan YangKeshav GopalFarah EatonRami Al BatranJohn R UssherPublished in: Basic & clinical pharmacology & toxicology (2023)
Liver-specific PDH deficiency is insufficient to promote an NAFLD phenotype. Nonetheless, hepatic PDH activity partially contributes to how the antianginal, ranolazine, improves glucose tolerance and alleviates hepatic steatosis in obesity.